27 March 2018 : Clinical Research
Plasma Levels of Homocysteine and the Occurrence and Progression of Rectal Cancer
Zhi LiuACDEF, Chunhui CuiABC, Xiaoyang WangBE, Alejandro Fernandez-EscobarE, Qunzheng WuE, Kai XuCE, Jiajia MaoB, Minxin JinB, Kexin WangAGDOI: 10.12659/MSM.909217
Med Sci Monit 2018; 24: CLR1776-1783
Abstract
BACKGROUND: The aim of this study was to investigate the association between plasma levels of homocysteine and the occurrence and progression of rectal cancer.
MATERIAL AND METHODS: The 320 study participants included healthy controls (n=80). and patients with rectal tumors (n=240), including 155 patients with rectal cancer, Stage I (n=32), Stage II (n=38), Stage III (n=50), and Stage IV (n=35), and patients with low-risk rectal adenomas (n=31), and high-risk rectal adenomas (n=54). All study participants had fasting blood samples taken, and plasma levels of homocysteine and carcinoembryonic antigen (CEA) were measured and compared. Receiver operating characteristic (ROC) curves were prepared to determine whether single, combined, or series levels of the two markers were diagnostic.
RESULTS: A significantly increasing trend in the plasma levels of homocysteine from the healthy controls, to the individuals with low-risk rectal adenoma, high-risk rectal adenoma, and Stage I–IV rectal cancer were found. There were no statistically significant differences in the area under the curve (AUC) between the two single factors of plasma homocysteine and CEA. The AUC showed that the use of combined or parallel measurement of plasma CEA and homocysteine had the greatest diagnostic associations.
CONCLUSIONS: Plasma levels of homocysteine were significantly associated with occurrence and progression of rectal cancer. The combined use of measurement of plasma homocysteine and CEA levels might have the potential to increase the diagnostic efficiency of screening for early rectal cancer.
Keywords: Carcinoembryonic Antigen, homocysteine, Rectal Neoplasms
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952